Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
While not required, passengers may choose to voluntarily inform TSA officers about their injectable medications at the security checkpoint
Special medical attention is important, among other things, in cases of: existing gastrointestinal conditions type 2 diabetes or other metabolic disorders cardiovascular disease or increased cardiovascular risk regular use of other medications previous intolerance to GLP-1 or GIP/GLP-1 medications unclear symptoms before starting treatment pregnancy, breastfeeding, or plans to become pregnant Patients can find more information about the tolerability of established GLP-1 medications, for example, on our page about side effects of Wegovy with semaglutide
Generally, people gained about 0.9 pounds per month after getting off the drugs
Proper storage preserves medication potency, ensuring consistent therapeutic effect
The results here highlight the role of GLP-1 RAs may play as a catalyst for earlier diagnosis and intervention in metabolic and related conditions
